Insider buying last 90 days
No open-market insider purchases were filed for GH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GH insider filing, plotted on the chart in Gekko.Open GH in Gekko
NASDAQ: GH
Guardant Health (GH) Stock Analysis & Forecast
Sep 28 close
$177.33+0.08 (0.0%)
Gekko Brief
AI summaryGuardant Health draws continued attention this week around its liquid biopsy franchise and valuation debate. Recent coverage points to FDA approval of Guardant360 CDx as the first liquid biopsy companion diagnostic for longitudinal testing in advanced or metastatic breast cancer, alongside 20 abstracts presented at WCLC 2026 on liquid biopsy and methylation-based lung cancer research. Separate pieces weigh whether the stock, up 73.4% year-to-date and roughly fivefold over three years, remains supported by future cash flows, while comparison articles set GH against peers such as CorVel and InfuSystem.
Shares close at $177.33, above both the 50-day average of $163.19 and the 200-day average of $122.43, with the 50-day above the 200-day. The GekkoIndex reads 49.7, placing it in the Neutral zone, down 1.3 over five days. Price sits 0.5% above Gekko Fair Value of $176.47, putting the two closely aligned. The 52-week range spans $59.03 to $183.51, with a one-month return of 5.2% and a six-month return of 109.6%.
Guardant Health's next earnings report is scheduled for 28 October 2026 after close, 29 days away and outside a typical 20-trading-day holding window. Analyst coverage from 22 firms is unanimously rated buy, with a consensus target of $196.38, implying 10.7% upside from current levels. Seasonality over the next 20 trading days has averaged -6% across 5 years, with gains in 1 of them, a pattern worth noting alongside the absence of recorded insider, Congress or unusual options activity in their respective windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Guardant Health price vs fair value
Close $177.33200-day averageGekko Fair Value $176.47
Guardant Health quick facts
- Market cap
- $23.80B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.51
- Revenue, TTM
- $1.18B
- Profit margin
- -38.3%
- Dividend yield
- —
- Beta
- 1.58
- Volume
- 1.32M avg 1.84M
- 1-year return
- +194.7%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.4%
- 50-day average
- $163.19
- 200-day average
- $122.43
- Next earnings
- Oct 28 after close
- Shares outstanding
- 134.2M
Guardant Health swing-trade checklist
Guardant Health scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $177.33 is above the 50-day ($163.19) and 200-day ($122.43) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
49.7, Neutral
Reading 49.7 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
0.5% above
Price is within 5% of Gekko Fair Value (0.5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 29 days
Next report Oct 28, 2026, 29 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.0% on average
From this point in the calendar, the next 20 trading days averaged −6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Guardant Health stock chart and price history
Guardant Health closed at $177.33 on Sep 28, 2026, +194.7% over the past year, inside a 52-week range of $59.03 to $183.51.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.2%
- 3 months
- +15.3%
- 6 months
- +109.6%
- 1 year
- +194.7%
The full GH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GH in Gekko
Follow Guardant Health through every session
Put GH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GH in GekkoFree for 7 days. No credit card required.
About Guardant Health
Guardant Health focuses on precision oncology, offering blood-based diagnostic tests along with data sets and analytical tools for patients dealing with cancer, both in the United States and abroad. Its work centers on liquid biopsy testing, with products such as Guardant360 and GuardantOMNI aimed at people with advanced-stage disease, and the Guardant Reveal Test supporting treatment decisions for those in earlier stages. The company also markets Guardant360 for tissue genotyping and a coronavirus detection test called Guardant-19.
Beyond its diagnostic products, Guardant Health runs GuardantINFORM, a research platform built on genomic data gathered from liquid biopsies of advanced cancer patients, and is developing tools including LUNAR-2 for early colorectal cancer detection and GuardantConnect, a platform meant to connect patients with relevant clinical trials. The company also works with biopharmaceutical firms and medical institutions, providing services such as companion diagnostic development, regulatory support, clinical study management, and kit fulfillment.
Guardant Health was founded in 2011 and is based in Redwood City, California. Its shares are listed on the NASDAQ under the ticker GH.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- guardanthealth.com
Guardant Health GekkoIndex: the smart money zone
Guardant Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.7, in the Neutral zone, down 1.3 points over five sessions.
49.7Neutral
Down 1.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 21 | +4.7% | +0.7% |
| Accumulation | 201 | +0.9% | +9.9% |
| Neutral (current zone) | 379 | +2.4% | +8.1% |
| Distribution | 60 | +2.1% | +5.2% |
| Selling | 10 | −2.9% | +8.1% |
Average GH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GH price, zone by zone.Track GH in Gekko
Is Guardant Health stock overvalued? Gekko Fair Value
Guardant Health trades 0.5% above Gekko Fair Value of $176.47, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Guardant Health shares are worth, recalculated every trading day.
$176.47
Gekko Fair Value, Sep 29, 2026
0.5% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open GH in Gekko
Guardant Health insider and Congress trading
No open-market insider purchases were filed for Guardant Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GH, plotted on the chart in Gekko.Open GH in Gekko
Buybacks
Guardant Health has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2025
- $45.01M
- As a share of market cap
- 0.19%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds GH.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Guardant Health earnings: next date and track record
Guardant Health reports on Oct 28, 2026, after the close (29 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected after the close, 29 days away
- EPS estimate
- −$0.29
- Revenue estimate
- $350.8M
5 of 8reports beat the EPS estimate
±11.7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Guardant Health reported Q2 2026 revenue of $335 million, up 44% year-over-year, with broad-based growth across Oncology, Biopharma & Data, and Screening. Oncology revenue grew 38% to $219 million with test volumes surging 63% to ~104,000 tests. Key milestones include FDA approval for Guardant360 Liquid CDx, a higher-throughput Shield workflow, ACS guideline inclusion, and UnitedHealth Group coverage for Shield. Reveal MRD product volume exceeded 100% growth year-over-year.
- Guidance
- No explicit forward-looking financial guidance was provided in this excerpt. Management highlighted ~$400 billion in addressable market potential across therapy selection, recurrence monitoring, cancer screening, and multi-disease screening as long-term growth drivers.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$0.89 est −$0.74 | $335.0M est $314.2M | +12.4% |
| May 7, 2026 | −$0.45 est −$0.47 | $301.7M est $279.2M | +3.7% |
| Feb 19, 2026 | −$0.50 est −$0.77 | $281.3M est $272.4M | −4.0% |
| Oct 29, 2025 | −$0.39 est −$0.48 | $265.2M est $267.6M | +32.8% |
| Jul 30, 2025 | −$0.44 est −$0.72 | $232.1M est $235.7M | −5.4% |
| Apr 30, 2025 | −$0.49 est −$0.85 | $203.5M est $211.4M | −1.3% |
| Feb 20, 2025 | −$0.62 est −$0.50 | $201.8M est $192.5M | −12.5% |
| Nov 6, 2024 | −$0.88 est −$0.74 | $191.5M est $189.0M | +21.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Guardant Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Guardant Health is $196.38, +10.7% from the last close, from 22 firms rating the stock in the last 90 days.
$196.38consensus 12-month target, +10.7% from the last close
Now $177.33Avg $196.38
Low $125High $225
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Bernstein | $210 | +18.4% |
| Sep 18 | Barclays | $200 | +12.8% |
| Sep 15 | Piper Sandler | $193 | +8.8% |
| Sep 15 | Craig-Hallum | — | — |
| Sep 9 | UBS | $225 | +26.9% |
+8.1%average 20-day move after past Neutral readings
−6.0%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Guardant Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Guardant Health averaged −6.0% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 2 of 5 |
| Next 10 trading days | −7.5% | 0 of 5 |
| Next 15 trading days | −7.0% | 1 of 5 |
| Next 20 trading days | −6.0% | 1 of 5 |
| Next 30 trading days | +6.6% | 2 of 5 |
For scale, GH’s typical 20-trading-day move in either direction is about 11.4%.
Guardant Health market cap and key statistics
Guardant Health’s market cap is $23.80B and revenue of $1.18B over the last twelve months.
Valuation
- Market cap
- $23.80B
- EPS, TTM
- −$3.51
- Gekko Fair Value
- $176.47
Trading
- Volume
- 1.32M
- Avg volume, 20 days
- 1.84M
- 52-week high
- $183.51
- 52-week low
- $59.03
- Shares outstanding
- 134.2M
Financials
- Revenue, TTM
- $1.18B
- Profit margin
- -38.3%
- Return on equity
- -4584%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.58
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.4%
Guardant Health stock news this week
Coverage of Guardant Health this week reads positive: 4 positive, 1 neutral and 0 negative headlines.
- Reviewing Guardant Health (NASDAQ:GH) & CorVel (NASDAQ:CRVL)Defense World, Sep 28
- Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x RunSimply Wall Street, Sep 27
- Guardant Health (GH) Rides Liquid Biopsy Growth Narrative With Valuation Still In FocusSimply Wall Street, Sep 25
- How FDA Approval Has Changed The Investment Story At Guardant Health StockSimply Wall Street, Sep 23
- Form 4 Guardant Health Inc For: 22 September By Investing.comInvesting.com Nigeria, Sep 22
- Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside PotentialDirectorsTalk Interviews, Sep 21
Guardant Health peers
Guardant Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Accumulation | 3.9% below |
| SOLVSolventum | Neutral | 16.4% below |
| EHCEncompass Health | Neutral | 7.6% above |
| DVADaVita | Accumulation | 15.9% below |
| BTSGBrightSpring Health Services | Accumulation | 7.4% below |
| ENSGEnsign | Neutral | 11.2% above |
A peer links to its own page where one exists.
Guardant Health stock FAQ
What is Guardant Health’s market cap?
Guardant Health’s market cap is $23.80B at the Sep 28, 2026 close of $177.33, with 134.2M shares outstanding.
What is the Guardant Health stock forecast?
The consensus analyst 12-month price target for Guardant Health is $196.38, +10.7% from the last close. Of the 22 firms that rated the stock in the last 90 days, 22 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Guardant Health stock overvalued or undervalued?
On Gekko’s estimate Guardant Health is about fair value: the Sep 28, 2026 close of $177.33 is 0.5% above Gekko Fair Value of $176.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Guardant Health report earnings next?
Guardant Health is expected to report on Oct 28, 2026, after the market closes (29 days away). Analysts expect earnings of −$0.29 per share on revenue of $350.8M. Guardant Health beat the earnings estimate in 5 of its last 8 reports, moving 11.7% on average across the report.
What is Guardant Health’s 52-week high and low?
Guardant Health’s 52-week high is $183.51 and its 52-week low is $59.03; it closed at $177.33 on Sep 28, 2026, +194.7% over the past year.
Is Guardant Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Guardant Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.